肿瘤原位疫苗研究进展OACSTPCD

Tumor vaccine is considered to be a promising immunotherapy method for tumors,but the high heterogeneity and mutation rate of tumors themselves greatly limit the development of traditional tumor vaccine.Compared with the traditional tumor vaccine,the tumor in situ vaccination can directly transform the tumor lesion itself into an"antigen factory",which has many advantages such as low systemic toxicity,high bioavailability,strong personalized degree,low time and economic cost,and has great therapeutic potential and clinical transformation value.It can induce local immunogenic cell death in tumors,promote the release of tumor antigens and immune-activating mediators,initiate or restart the"tumor-immune cycle"that has been silenced in the body,and further induce tumor-specific immune memory.This paper focused on tumor in situ vaccination,introduced in detail its anti-tumor mechanism and specific strategies with key clinical results,revealed the application potential and challenges of tumor in situ vaccination,and provides theoretical references for the design of tumor in situ vaccination.